Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Depreciation and Depletion: 2021-2025

Historic Depreciation and Depletion for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $1.4 million.

  • Krystal Biotech's Depreciation and Depletion rose 7.69% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 8.73%. This contributed to the annual value of $6.0 million for FY2024, which is 19.83% up from last year.
  • According to the latest figures from Q3 2025, Krystal Biotech's Depreciation and Depletion is $1.4 million, which was up 7.69% from $1.3 million recorded in Q2 2025.
  • Krystal Biotech's 5-year Depreciation and Depletion high stood at $1.8 million for Q2 2024, and its period low was $438,000 during Q1 2021.
  • Moreover, its 3-year median value for Depreciation and Depletion was $1.4 million (2024), whereas its average is $1.4 million.
  • In the last 5 years, Krystal Biotech's Depreciation and Depletion soared by 142.91% in 2023 and then dropped by 27.78% in 2025.
  • Over the past 5 years, Krystal Biotech's Depreciation and Depletion (Quarterly) stood at $449,000 in 2021, then soared by 132.29% to $1.0 million in 2022, then spiked by 44.49% to $1.5 million in 2023, then fell by 7.30% to $1.4 million in 2024, then grew by 7.69% to $1.4 million in 2025.
  • Its Depreciation and Depletion was $1.4 million in Q3 2025, compared to $1.3 million in Q2 2025 and $1.4 million in Q1 2025.